Northern Trust Corp Praxis Precision Medicines, Inc. Transaction History

Northern Trust Corp

  • $572 Billion
  • Q1 2024

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023
BUY
$0.87 - $1.71 $152,694 - $300,123
175,511 Added 145.65%
296,009 $506,000
Q2 2023

Aug 11, 2023
SELL
$0.83 - $1.18 $237,135 - $337,131
-285,705 Reduced 70.34%
120,498 $138,000
Q1 2023

May 15, 2023
BUY
$0.8 - $4.98 $43,465 - $270,573
54,332 Added 15.44%
406,203 $329,000
Q4 2022

Feb 13, 2023
SELL
$1.88 - $2.49 $35,199 - $46,620
-18,723 Reduced 5.05%
351,871 $837,000
Q3 2022

Nov 14, 2022
SELL
$2.5 - $4.77 $2,180 - $4,159
-872 Reduced 0.23%
370,594 $841,000
Q2 2022

Aug 12, 2022
BUY
$1.75 - $11.34 $94,246 - $610,715
53,855 Added 16.96%
371,466 $911,000
Q1 2022

May 13, 2022
BUY
$10.21 - $20.29 $33,601 - $66,774
3,291 Added 1.05%
317,611 $3.24 Million
Q4 2021

Feb 08, 2022
BUY
$16.76 - $22.99 $269,768 - $370,047
16,096 Added 5.4%
314,320 $6.19 Million
Q3 2021

Nov 15, 2021
BUY
$13.15 - $22.56 $986,749 - $1.69 Million
75,038 Added 33.62%
298,224 $5.51 Million
Q2 2021

Aug 13, 2021
BUY
$18.28 - $33.05 $1.87 Million - $3.39 Million
102,496 Added 84.93%
223,186 $4.08 Million
Q1 2021

May 12, 2021
SELL
$29.34 - $60.2 $194,670 - $399,427
-6,635 Reduced 5.21%
120,690 $3.95 Million
Q4 2020

Feb 11, 2021
BUY
$27.25 - $55.82 $3.47 Million - $7.11 Million
127,325 New
127,325 $7.01 Million

Others Institutions Holding PRAX

# of Institutions
1
Shares Held
75K
Call Options Held
0
Put Options Held
0
View Full List

About Praxis Precision Medicines, Inc.

PRAX Quotes by TradingView
  • Ticker PRAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,576,100
  • Market Cap $1.79B
  • Description
  • Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...
More about PRAX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email